Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients

Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients

Oct 08, 2018
Source URL: https://qa1.novartis.us/news/media-releases/novartis-announces-fda-filing-acceptance-siponimod-baf312-first-and-only-oral-drug-shown-delay-disability-progression-typical-spms-patients-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-announces-fda-filing-acceptance-siponimod-baf312-first-and-only-oral-drug-shown-delay-disability-progression-typical-spms-patients-0